Form 8-K - Current report:
SEC Accession No. 0001213900-24-108370
Filing Date
2024-12-12
Accepted
2024-12-12 16:18:06
Documents
16
Period of Report
2024-12-12
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea022449301-8k_abpro.htm   iXBRL 8-K 32183
2 PRESS RELEASE, DATED DECEMBER 12, 2024 ea022449301ex99-1_abprohold.htm EX-99.1 17690
7 GRAPHIC ex99-1_001.jpg GRAPHIC 1699
  Complete submission text file 0001213900-24-108370.txt   277941

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abp-20241212.xsd EX-101.SCH 3855
4 XBRL DEFINITION FILE abp-20241212_def.xml EX-101.DEF 26756
5 XBRL LABEL FILE abp-20241212_lab.xml EX-101.LAB 36996
6 XBRL PRESENTATION FILE abp-20241212_pre.xml EX-101.PRE 25380
18 EXTRACTED XBRL INSTANCE DOCUMENT ea022449301-8k_abpro_htm.xml XML 5990
Mailing Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013
Business Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013 248-890-7200
Abpro Holdings, Inc. (Filer) CIK: 0001893219 (see all company filings)

EIN.: 871013956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41224 | Film No.: 241545093
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)